Targeted therapies in neuroendocrine neoplasms
Journal Title: OncoReview - Year 2012, Vol 2, Issue 3
Abstract
The primary treatment of gastrointestinal neuroendocrine tumors is surgery, and its extent depends on the clinical stage of cancer. In advanced disease medical therapy is used. One possible form of treatment is biological therapy and radionuclide therapy (PRRT, peptide receptor radionuclide therapy) using radiolabeled somatostatin analogues. The effects of these treatments can improve the combinations of radioactive labeled somatostatin analogues, intra-arterial administered, and the use of radio sensitizing drugs combined with PRRT or PRRT combined with new targeted therapeutic agents such as sunitinib or everolimus. New targeted agents (angiogenesis inhibitors, single and multiple tyrosine kinase inhibitors and new somatostatin analogues, such as pasyreotyd) also evaluated in II and III phase clinical trials. Currently, there are several studies on the efficacy of a combination of different, present and new treatments. PRRT with the combination of sunitinib or everolimus or sequential use of PRRT and one of these compounds may be a promising solution for the treatment of patients with pancreatic endocrine tumors.
Authors and Affiliations
Violetta Rosiek, Beata Kos-Kudła
Keywords
Related Articles
- EP ID EP53164
- DOI -
- Views 243
- Downloads 0
Paraneoplastic neurological syndrome in the course of breast cancer
Paraneoplastic neurological syndromes (PNS) are a group of rarely observed disorders, accompanying about 1% of cancer diseases. They have a typically aggressive course, leading to profound and essentially irreversible di...
Mindfulness in the treatment of chronic pain and improvement in the quality of life of both oncological and non-oncological patients
Pain, which accompanies almost every third Pole, is an ever greater medical, psychological and social challenge. Relieving pain, and chronic one in particular, is now becoming one of the most important tasks for contempo...
New view on advanced renal cancer targeted therapies efficacy – controversies
During the last few years the strong progress on new therapies in advanced/metastatic renal cell carcinoma has been observed. It is mostly related to understanding of significant renal cell cancer molecular basics. Previ...
Leczenie okołooperacyjne gruczolakoraka przełyku, połączenia przełykowo-żołądkowego oraz żołądka; nowe standardy postępowania i kontrowersje
Rak przełyku, połączenia przełykowo-żołądkowego oraz żołądka to duży problem diagnostyczny i terapeutyczny. Nawet po zabiegach chirurgicznych (R0) odsetek przeżyć 5-letnich jest niezadowalający. Chemioterapia okołooperac...
Early diagnostics and prevention of anthracycline-induced cardiomyopathy – the role of cardiologist
Anticancer antibiotics, anthracyclines, may cause severe left ventricle systolic dysfunction that is associated with poor clinical prognosis. In this review, we discuss the mechanisms and risk factors of anthracycline-in...